Choosing the Right Dopamine Agonist for Patients With Parkinson's Disease

C. Lebrun-Frenay, M. Borg


Curr Med Res Opin. 2002;18(4) 

In This Article


Dopamine agonists make an important contribution to the management of a patient with the early symptoms of Parkinson's disease, and carry the hope of a more acceptable long-term side-effect profile. In addition, dopamine agonists permit the fine-tuning that the more advanced patient with more complex needs requires. The rewards of using dopamine receptor agonists without levodopa in patients with early symptoms of PD, as well as combined with levodopa in more advanced patients, is likely to reinforce motivation to continue the use of these agents. Nevertheless, all dopamine agonists are not evenly matched according to their smooth use in terms of flexible indication in PD, side-effect profile and titration schedule. According to these three main features and the French practical experience, Trivastal retard 50® (piribedil) emerges as one of the most convenient dopamine agonists in daily practice for the treatment of parkinsonian patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.